

Press Release:

Date: April 27th 2021

Dubai, UAE and Florida USA April 27, 2021.

Cureleads, MENA Biopharma specialty company based in Dubai and Beirut, announced today collaboration with SGN Nanopharma, Inc. an innovative, clinical-stage, and revenue-generating developer of nanotherapeutics and Wellesta Holdings, a Singapore-based Pharmaceutical company with a market presence in India & South East Asia, to commercialize SGN nano-therapeutics for patients with dry eye disease across Middle East and North Africa. The first product to be launched will be in the Ophthalmic category. This collaboration aims to establish a series of superior nanotherapeutics in large and growing therapeutic categories with significant unmet needs of patients and healthcare professionals.

Talking about the collaboration, Dr. Navdeep Jaikaria, Founder, Chairman, and CEO of SGN Nanopharma, Inc., said, "We are very excited about this partnership. We plan to bring multiple products to these growing and emerging markets of Asia and MENA through our partners Wellesta and Cureleads."

Mohamad Rammal, CEO of Cureleads, said, "we are excited to bring the nanotherapeutics technology for patients with dry eye disease across the Middle East and North Africa. This collaboration with SGN Nanopharma will have a huge impact on patients in the MENA region."

Milan Paleja of Wellesta said that "we are excited to bring enhanced technology products for our patients in Asia. This will help our dry-eye patients achieve much better outcomes compared to currently available products in the market. This collaboration with SGN Nanopharma is a major step towards getting higher efficiency products for our patients in Asia."

<https://sgn.bio/>

<https://www.wellesta.com/about-us.html>

<http://www.cureleads.com/>